OOIR: Observatory of International Research

Papers

(The H4-Index of Pharmacology & Therapeutics is 63. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-07-01 to 2025-07-01.)

Article	Citations
WITHDRAWN: 17th International conference on bioactive lipids in cancer, inflammation and related diseases virtual special issue	404
Measuring brain docosahexaenoic acid turnover as a marker of metabolic consumption	295
Editorial Board	285
Endothelial dysfunction as a complication of anti-cancer therapy	247
HIV-associated neurotoxicity and cognitive decline: Therapeutic implications	237
Retinoid dynamics in vision: from visual cycle biology to retina disease treatments	218
Collateral lethality: A unique type of synthetic lethality in cancers	193
Exploiting the obesity-associated immune microenvironment for cancer therapeutics	190
Non-canonical G protein signaling	188
Adenosine receptor signalling as a driver of pulmonary fibrosis	171
Inflammation, lipids, and pain in vulvar disease	163
Potential neonatal toxicity of new psychoactive substances	157
The role of macrophages in asthma-related fibrosis and remodelling	154
Unfolded protein responses: Dynamic machinery in wound healing	149
New therapeutic horizons for plasma phospholipid transfer protein (PLTP): Targeting endotoxemia, infection and sepsis	142
Vasculogenic mimicry, a complex and devious process favoring tumorigenesis – Interest in making it a therapeutic target	131
Efficacy and safety of immune-modulating therapy for primary sclerosing cholangitis: A systematic review and meta-analysis	124
Matrikines in the skin: Origin, effects, and therapeutic potential	124
Regulatory lipid vicinal diols counteract the biological activity of epoxy fatty acids and can act as biomarkers and mechanisms for disease progression	123
In cancer, all roads lead to NADPH	123
Myeloid cells in the era of cancer immunotherapy: Top 3 unanswered questions	121
Sulfoconjugation of protein peptides and glycoproteins in physiology and diseases	119
Pharmacological modulation of respiratory control: Ampakines as a therapeutic strategy	118
Targeting the p38α pathway in chronic inflammatory diseases: Could activation, not inhibition, be the appropriate therapeutic strategy?	112
Boron in cancer therapeutics: An overview	111

The phospholipase A2 superfamily as a central hub of bioactive lipids and beyond	109
Contribution of non-selective membrane channels and receptors in epilepsy	101
TLR4 biased small molecule modulators	96
Sleep apnea and pulmonary hypertension: A riddle waiting to be solved	95
Management of drug-resistant hypertension as a heterogeneous disorder	93
Harnessing and delivering microbial metabolites as therapeutics via advanced pharmaceutical approaches	93
Prostate Cancer Biomarkers: From diagnosis to prognosis and precision-guided therapeutics	90
Endothelial function and dysfunction: Impact of sodium-glucose cotransporter 2 inhibitors	90
Novel approaches to target fibroblast mechanotransduction in fibroproliferative diseases	89
Is the peroxisome proliferator-activated receptor gamma a putative target for epilepsy treatment? Current evidence and future perspectives	88
Cell-based therapies for vascular regeneration: Past, present and future	87
Imaging neuroinflammation with TSPO: A new perspective on the cellular sources and subcellular localization	84
Recent drug design strategies and identification of key heterocyclic scaffolds for promising anticancer targets	83
Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance	83
TAAR1 as an emerging target for the treatment of psychiatric disorders	82
Dysregulation of metabolic pathways in pulmonary fibrosis	81
Targeting Sirtuin1 to treat aging-related tissue fibrosis: From prevention to therapy	80
Bispecific antibodies for the treatment of neuroblastoma	80
Natural products that alleviate depression: The putative role of autophagy	79
Therapeutic implications of impaired nuclear receptor function and dysregulated metabolism in Wilson's disease	78
Pharmacological treatment of cardiogenic shock – A state of the art review	78
Corrigendum to “The role of CD71+ erythroid cells in the regulation of the immune response” [Pharmacology & Therapeutics 228 (2021) 107927]	76
Traditional Chinese Medicine (TCM) in the treatment of COVID-19 and other viral infections: Efficacies and mechanisms	71
Recent advances in metabolism and toxicity of tyrosine kinase inhibitors	71
Editorial Board	71
Wnt signaling: A prospective therapeutic target for chronic pain	70
G protein-coupled receptor-effector macromolecular membrane assemblies (GEMMAs)	70
Review: Sex-related differences in the treatment of cardiac arrhythmia	69
Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance	67
PGRMC1: An enigmatic heme-binding protein	67
Interactions between NSAIDs, opioids and the gut microbiota - Future perspectives in the management of inflammation and pain	67
CircRNAs as upstream regulators of miRNA//HMGA2 axis in human cancer	66
Emerging role of ferroptosis in breast cancer: New dawn for overcoming tumor progression	66
HDL-based therapeutics: A promising frontier in combating viral and bacterial infections	66
The pathomimetic oAβ25–35 model of Alzheimer's disease: Potential for screening of new therapeutic agents	66
DNA methylation in cell plasticity and malignant transformation in liver diseases	65
Entering the TiME machine: How age-related changes in the tumor immune microenvironment impact melanoma progression and therapy response	64
Addiction and the kynurenine pathway: A new dancing couple?	64
Stabilizing the neural barrier – A novel approach in pain therapy	63
A systematic review on renal effects of SGLT2 inhibitors in rodent models of diabetic nephropathy	63